Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Semaglutide GLP-1, Mounjaro, Wegovy, and Ozempic can all help patients achieve considerable weight loss, leading to dramatically improved health outcomes for overweight and obese patients
Retailers who market it as such are in breach of US law
Wegovy has favorable formulary placement among GLP-1 weight loss medications
Weight-related conditions that may qualify at BMI 27 to under 30 Type 2 diabetes Prediabetes High blood pressure Dyslipidaemia, including raised cholesterol Obstructive sleep apnoea Cardiovascular disease Lower thresholds for some ethnic backgrounds For people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family background, a lower BMI threshold is commonly applied usually reduced by around 2.5 kg/m because cardiometabolic risk occurs at lower BMI in these populations
